PBPauline Brevet

Pauline Brevet

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pauline Brevet has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Auto-anticorps dans la polyarthrite rhumatoïde : apport diagnostique et pronostique en pratique courante

    by Pauline Brevet, Léna Le Goareguer, Olivier Boyer, Thierry Lequerre, Manuel Freret, Olivier Vittecoq

  • Open Access

    Women with spondyloarthritis occurring in the peripartum period develop a singular phenotype

    by Baptiste de Maleprade, Baptiste Gérard, Pauline Brevet, Camille Prum-Delepine, Gilles Avenel, Nicolas Sens, Sophie Pouplin, Stéfan Jacques Darmoni, Julien Grosjean, Olivier Vittecoq, et al.

    Background: Spondyloarthritis (SpA) has specific features in women and may be triggered by parturition. The peripartum period is marked by musculoskeletal remodelling and IL-17 secreting cell activation to enable childbirth. We therefore hypothesized that peripartum SpA might predominantly involve the entheses and be less dependent on HLA-B27 and TNFα. Methods: We conducted a retrospective, observational, case-control study using the Rouen University Hospital’s clinical data warehouse. Delivery dates and symptom onset were available for 154 women with SpA. Characteristics were compared between cases (with peripartum SpA) and controls. Results: We identified 58 cases and 96 controls. HLA-B27 (37.3% vs. 52.3%, p-value: 0.04), anterior chest syndrome (74.1% vs. 54.7%, p-value: 0.012 and psoriasis (37.9% vs. 16.8%, p-value: 0.004 were significantly associated with peripartum SpA. Lower rates of biological inflammatory syndrome at TNFα inhibitor introduction, (22.2% vs. 48.1%, p-value: 0.003), of radiographic sacroiliac damage (4% vs. 18.6%, p-value: 0.012 and of MRI sacroiliitis (30.6% vs. 47.4%, p-value: 0.046 were observed in women with peripartum SpA. Also, a lower retention rate of TNFα inhibitors was observed in women with peripartum SpA, 45.6% at 12 months, versus 71.2% controls (Odd ratio: 2.56 [95% CI: 1.34–4.95]). Multivariate survival analysis found a hazard ratio for TNFα inhibitor discontinuation of 2.43 (95% CI: 1.62–3.65) within the first two years of treatment. Conclusions: Our study highlights a distinct phenotype of peripartum SpA, and a lower retention rate of TNFα inhibitors suggesting a worse response to these class of bDMARD. Trial registration: As we conducted a retrospective study without health care intervention, no prospective registration was done.

  • Open Access

    Early postoperative activity tracking shows excessive ambulation and poor adherence to recommendations after hallux valgus surgery

    by Julien Beldame, Alessandro Civinini, Pauline Brevet, Nicolas Kloek, Timothée Gillot, Matthieu Lalevée, Marie-Anne Melone

  • Evaluation by modern imaging of anterior chest wall involvement in axial spondyloarthritis with or without chest complaint

    by Pauline Brevet, Camille Mercier, Baptiste Gérard, Marie Kozyreff-Meurice, Gilles Avenel, Thierry Lequerré, Paul Michelin, Olivier Vittecoq


  • Could the anti-modified protein antibody concept help better define seronegative rheumatoid arthritis?

    by Pauline Brevet, Manuel Fréret, Eric Barat, Thierry Lequerré, Olivier Boyer, Olivier Vittecoq


  • Open Access

    On difficulties to define prognostic factors for clinical practice in rheumatoid arthritis

    by Olivier Vittecoq, Pauline Brevet, Baptiste Gerard, Thierry Lequerre

    In rheumatoid arthritis (RA), the identification of prognostic factors (PF) capable of predicting disease outcome, response to treatment or success of dose reduction is an important issue, as these factors are intended to serve as a basis for decision-making. The task is complex from the outset, as the definition of disease prognosis or therapeutic prognosis is not uniquevocal. The heterogeneity of the definitions used partly explains the failure to identify PF that can be applied at an individual level. But other factors also contribute. First, the scope of the disease studied is too broad, including nosologically different entities. Second, potential PF are only measured at a single point of time, whereas changes over a period of time should be taken into account to a greater extent, not forgetting the potential impact of the treatment received during this period. Beyond these limiting factors, one of the main obstacles to the identification of PF is probably the fact that the phase of the disease is not sufficiently taken into account. Predicting the disease outcome when it is well established is a more complex challenge than when it is just beginning, as many factors are likely to interfere. The same applies to therapeutic PF, which should be determined according to disease duration. Difficulties also arise from the approaches used, which are often restricted to a single field of interest whereas they should be much more integrative and call on new large-scale data analysis tools with a view to precision medicine. In RA, prognosis can be defined at two levels: disease outcome, including joint damage and risk of extra-articular manifestations and/or complications, and treatment outcome, including response to therapy, risk of adverse effects and drug-free remission.


  • A pilot study of refractory enthesitis treated with CO2 laser in spondyloarthritis and psoriatic arthritis

    by Pauline Brevet, Clara Duclos, Baptiste De Maleprade, Pierre Protat, Charles Patenere, Julien Michaud, Julien Grosjean, Thierry Lequerré, Eric Barat, Mehdi Roudesli, et al.


  • Open Access

    Impact of the Clinical Pharmacist in Rheumatology Practice: A Systematic Review

    by Eric Barat, Annaelle Soubieux, Pauline Brevet, Baptiste Gerard, Olivier Vittecoq, Thierry Lequerre, Catherine Chenailler, Rémi Varin, Claire Lattard

    This is a systematic literature review on the impact of pharmacists in rheumatology, conducted using the PubMed®, CINAHL®, Cochrane Library®, and Web of science® databases and using the PRISMA 2020 checklist. This review was conducted from 2000 to June 2024. A quality analysis was performed. The selection of articles, as well as all analyses, including quality analyses, were conducted by a pair of pharmacists with experience in rheumatology, and included 24 articles. This study highlights the growth of clinical pharmacy activities in rheumatology and the positive influence of clinical pharmacists on patient care. The implementation of such initiatives has the potential to improve medication adherence, reduce medication-related risks, and optimize associated healthcare costs. All these pharmaceutical interventions aim to make the patient care journey smoother and safer. Additionally, the diversity of available pharmaceutical services caters to the varied needs of rheumatology. Furthermore, outpatient clinical pharmacy is also explored in this field and garners interest from patients. The vast majority of studies demonstrate significant improvement in patient care with promising performance outcomes when pharmacists are involved. This review highlights the diverse range of interventions by clinical pharmacists in rheumatology, which is very promising. However, to better assess the benefits of clinical pharmacists, this activity needs further development and evaluation through controlled and randomized clinical research programs.


  • Open Access

    An Overview of Opioid Prescription Patterns among Non-Opioid Users Following Emergency Department Admission

    by Miriam Zeino, Romain Léguillon, Pauline Brevet, Baptiste Gerard, Catherine Chenailler, Johanna Raymond, Lucas Bibaut, Sophie Pouplin, Luc Marie Joly, Rémi Varin, et al.

    The evolving landscape of opioid prescription practices necessitates a comprehensive understanding of emerging patterns, particularly among new opioid users discharged from emergency departments. This study delves into the intricate realm of opioid utilization by elucidating the prevalence of their prescriptions. A retrospective analysis of electronic health records was conducted, including a cohort of 71 patients who received opioid prescriptions upon discharge from emergency departments from 1 January 2022 to 30 June 2022. Demographic characteristics and prescription details were systematically examined. This study illuminates tramadol’s prominence, with 84% of prescriptions and a Defined Daily Dose (DDD) morphine equivalent of 60 mg, as the primary choice as a new opioid, a finding that draws attention due to the closely aligned dosages with morphine equivalents. This discovery prompts a critical reassessment of tramadol’s therapeutic role, considering its multifaceted nature encompassing serotonergic effects and heightened fall risks. This study advocates for a nuanced and vigilant approach to tramadol prescription, cognizant of its potential risks and therapeutic implications, and highlights the imperative of optimizing data quality and traceability within electronic health records to enhance patient care and facilitate future research endeavors.